On the 18th, Foresee Pharmaceuticals announced the shipment of its first batch of CAMCEVI, a new formulation drug for prostate cancer. The CAMCEVI 42 mg six-month depot injection was produced by the French contract manufacturer Fareva Pau and has been transported to the designated storage facility of its partner, Accord Healthcare, in Germany. This marks the initial launch of CAMCEVI in the German market and Foresee's official entry into the EU pharmaceutical market.
Read more
